⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CRVO News
CervoMed Inc. Common Stock
Form 8-K
sec.gov
CRVO
CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026
globenewswire.com
CRVO
Form 8-K
sec.gov
CRVO
Form 8-K
sec.gov
CRVO
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
globenewswire.com
CRVO